Schaut Euch mal Bradley Pharmaceuticals aus den USA an - 500 Beiträge pro Seite

[boardpatrol1]

Ich wollte Euch sagen, daß ich in Bradley (BPRX)investiert bin. Alle Infos unter yahoo.com und www.bradpharm.com . Insbesondere gibt es auf der Hauptseite Links auf Presseartikel und Konferenzen, die man sich anschauen sollte .Leider sind die Umsätze in Deutschland noch sehr gering.

[boardpatrol1]

Hallo ! Soryy hab noch vergessen zu sagen, daß ich mit Umsätzen, Aktienumsätze meinte. Zur Verdeutlichnug des Beitrag wäre dieser link hier auch noch interressant. Aber keine Frage ,wenn der Gesammtmarkt, so wie heute, in die Grätsche geht...bleibt eine Auswirkung auf BPRX natuerlich auch nicht aus.
http://www.quicken.com/investments/strategies/?symbol=BPRX

[boardpatrol1]

ps: Ich gebe zu , daß mein Boardname etwas mißverständlich ist. Ich bin weder beruflich noch privat bei einem Board ,incl. wallstreet-online, engagiert und beteilige mich hier nur als normaler privater Anleger mit persöhnlicher Meinung.

[boardpatrol1]

09.07. 20:33
Bradley Pharma bekräftigt Planzahlen
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)

Bradley Pharmaceuticals teilte mit, die Erwartungen des Marktes im zweiten Quartal erreichen oder gar übersteigen zu können. Das Unternehmen wird voraussichtlich einen Gewinn je Aktie von 14 cents ausweisen, von 6 cents im Vorjahr. Der Umsatz wird erwartungsgemäß im gleichen Vergleichszeitraum um 53 Prozent auf mindestens 9 Millionen Dollar wachsen.

Die Aktien des Unternehmens können zuletzt um 13.69 Prozent auf 10.23 Dollar ansteigen.

[boardpatrol1]

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Press Release Source: Bradley Pharmaceuticals, Inc.


Bradley Pharmaceuticals Announces Stock Repurchase Plan and Projects Strong Third Quarter Results
Friday September 27, 7:45 am ET


FAIRFIELD, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (Nasdaq: BPRX - News) today announced a program to repurchase up to $4 million in market value of shares of Bradley Common Stock in open market transactions over the next 24 months, in compliance with Rule 10b-18 under the Securities Exchange Act.
ADVERTISEMENT


Shares of repurchased Common Stock will be held in the Company`s treasury and used for purposes deemed appropriate by the Board of Directors. With virtually no debt and approximately $24 million in cash and short term investments, Bradley Pharmaceuticals will continue to be in a strong financial position, including the ability to expand through acquisition and/or licensing, beyond its current product lines into future growth opportunities.

Daniel Glassman, President and CEO of Bradley Pharmaceuticals, stated, "This stock repurchase program emphasizes the Management Team`s confidence in the continued growth and enhanced shareholder value being achieved by Bradley. The Company continues to experience growth in sales and profits, as well as an expansion of brand lines. Moreover, Bradley has strengthened its infrastructure with the addition of key management and sales experienced professionals. The Company also has expanded its commitment to interactive relationship building with physicians. By the end of 2002, both Bradley operating units, Doak Dermatologics and Kenwood Therapeutics, will have sponsored exciting medical symposia, bringing together key, leading and influential physicians to share their clinical experience and treatment insights with specialty colleagues in specific therapeutic areas."

As Third Quarter 2002, ending September 30, closes, Bradley`s Management Team is confident that sales and profits will meet or exceed established goals. Bradley Management looks forward to announcing Third Quarter financial results on October 29, 2002.

Bradley Pharmaceuticals, Inc. primarily markets prescription niche category therapies to targeted, high-potential prescribing physicians throughout the United States and in 34 international markets. The Doak Dermatologics subsidiary provides dermatology brands and the Kenwood Therapeutics division delivers gastroenterology, nutritional and respiratory brands. The Company has achieved success through its marketing, sales and financial control core strengths, acquiring and enhancing brands, often introducing product line extensions to fill unmet needs.

Important announcement:
3rd Qtr. Earnings Release
Tuesday, October 29, 2002 at
10 AM EDT.
Earnings Conference Call, Tuesday, October 29, 2002 at
2 PM EDT.
Bradley Pharmaceuticals common stock is quoted on the NASDAQ market under the symbol BPRX.

Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com

Except for historical and factual information, this press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that address activities, events, or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates and predictions of future financial performance. All forward-looking statements are based on assumptions made by Bradley based on its experience and perception of historical trends, current conditions, expected future developments, and other factors it believes are appropriate under the circumstances. These statements are subject to numerous risks and uncertainties, many of which are beyond Bradley`s control, including Bradley`s ability to maintain CARMOL® sales, effectively purchase or integrate new products into its portfolio or effectively react to other risks described from time to time in Bradley`s SEC filings. Further, Bradley cannot predict the impact on its business of any future approvals of generic versions of its products or of other competing products. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

[boardpatrol1]

einfach mal so...

[boardpatrol1]

Press Release Source: Bradley Pharmaceuticals, Inc.


Bradley Pharmaceuticals Announces the Introduction of a Unique New Acne/Rosacea Treatment: ROSULA(R) Lotion
Monday January 27, 7:45 am ET


FAIRFIELD, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals, Inc. (Nasdaq: BPRX - News), announces the introduction of prescription-only ROSULA® Lotion for the topical treatment of acne and rosacea. ROSULA® Lotion offers patients the benefits of antibacterial, keratolytic and moisturizing agents in an alcohol-free formulation. ROSULA® Lotion will be marketed to the dermatology community.
Capitalizing on the premise, "The difference is Urea," ROSULA® Lotion is comprised of two well-accepted acne/rosacea agents which are Sodium Sulfacetamide and Sulfur. With the addition of Urea, Doak Dermatologics presents a significant departure from traditional therapies to position ROSULA® Lotion as the next generation in acne/rosacea treatment.

ROSULA® Lotion efficiently helps to reduce comedones, papules, pustules, redness and inflammatory skin lesions in a non-irritating manner. Urea gently lifts away rough, flaky skin and works synergistically as a keratolytic with Sulfur to open pores and keep them open, which is an integral part of effective acne treatment. Additionally, Urea, in combination with Sodium Sulfacetamide and Sulfur, also soothes and relieves redness and inflamed skin, providing relief for rosacea sufferers.

Bradley Pharmaceuticals President and CEO Daniel Glassman, stated, "Bradley looks forward to entering the huge and highly-competitive market of acne/rosacea treatments with the unique therapeutic approach represented by Urea. Approximately 3 out of every 4 patient visits to dermatologists are for the treatment of acne or rosacea. ROSULA® Lotion, the Company`s initial entry into this large market, will establish a unique niche base to support other future Bradley brand introductions in the acne/rosacea area. An extensive promotional campaign is being launched, including direct mail and professional journal advertising, intensive physician detailing and heavy sampling. The Management Team expects that the introduction of ROSULA® Lotion will add significantly to the sales generated by the Doak Dermatologics subsidiary."

ROSULA® Lotion is one of two major products launched by Bradley in January, 2003. AnaMantle® HC, a new prescription hemorrhoid treatment, is being introduced by Bradley through its Kenwood Therapeutics division.

Bradley Pharmaceuticals, Inc., is a specialty pharmaceutical company marketing prescription niche therapies to highly targeted physician audiences in the United States and in 31 international markets. Dermatology brands are delivered by the Doak Dermatologics subsidiary and the Kenwood Therapeutics division provides gastroenterology, nutritional and respiratory therapies. Following the strategy Acquire, Enhance, Grow, the company has achieved success by acquiring and managing the life cycle of brands that fill unmet needs.

Important announcement:
4th Qtr. 2002 Earnings PR
Wednesday, February 26, 2003
Earnings Conference Call, Wednesday, February 26, 2003 at 2 PM EST.


Daniel Glassman will present at the Tenth Annual Emerald Groundhog Day Investment Forum on Thursday, February 6, 2003 at 8:45 AM EST.

Daniel Glassmanwill present at the Raymond James & Associates 24th Annual Institutional Investors Conference on Tuesday, March 4, 2003 at 10:35 AM EST.

See http://www.bradpharm.com Calendar of Events for additional information.

Bradley Pharmaceuticals common stock is quoted on the NASDAQ market under the symbol BPRX.

Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com

Except for historical and factual information, this press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that address activities, events, or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates and predictions of future financial performance. All forward-looking statements are based on assumptions made by Bradley based on its experience and perception of historical trends, current conditions, expected future developments, and other factors it believes are appropriate under the circumstances. These statements are subject to numerous risks and uncertainties, many of which are beyond Bradley`s control, including Bradley`s ability to maintain CARMOL® sales, effectively purchase or integrate new products into its portfolio or effectively react to other risks described from time to time in Bradley`s SEC filings. Further, Bradley cannot predict the impact on its business of any future approvals of generic versions of its products or of other competing products. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.




--------------------------------------------------------------------------------
Source: Bradley Pharmaceuticals, Inc.

[Mannerl]

sieht ganz interessant aus!

muss ich mir in die Liste legen!

Wie bist Du denn auf die Aktie gekommen?

MFG

[boardpatrol1]

Also ich hab die Biotech und Pharmabranche schon lang im Auge.